HIGH FLYERS THINK TANK
Emerging diseases Ready and waiting?
The Shine Dome, Canberra, 19 October 2004
Mixed breakout groups
Dr Jim Peacock
President, Australian Academy of Science
We are going to regroup
in some mixed groups. This is very important, again. Some excellent material
has come up in these discussions, and you would have noted that there
were some universalities or common points brought up from each of them.
I think that really picks up the last point of discussion, about multidisciplinary
teams in different areas.
Everyone talked about the assessment
of risk. We don't seem to be particularly strong at that or to have
very good mechanisms in place for it.
The question of investment
came up. Everyone saw that more investment was needed in responding to
emerging diseases. Who is going to make it? Where is the money going to
come from? How would you go about persuading, if it is to be government
or industry bodies or both? It is probably not private companies, but
maybe there are ways of bringing private companies in as well.
And then there is the matter
of capacity in the different disciplines that are important in each of
the areas we have discussed. Clearly we recognise that in some disciplines,
or parts of some disciplines, we have some excellent capacity. But I heard
one of the groups talking about the very small number of field plant pathologists
left in Australia – this being, I think, an order of magnitude less
than the veterinary people in the field. So there are some obvious problems.
I remain surprised that you
have not talked very much about new science, and whether there are some
developments in science that you think could change the status quo. Are
there developments in our science that we should be using as one of the
arguments, or levers, to obtain more investment in research? I think there
was one suggestion of ‘Have microarray, will travel into the field'
and so on, but there must be other things that have changed quite dramatically
in the last, say, two decades that might enable us to make a more telling
argument to our investment masters.
The question of ‘beyond
the coastline of Australia' came up I think in every group. Surely
one of the major strategies that should be considered is working beyond
the coastline, in partnership with other countries that may be sources
of disease. There may be other groups that have particular scientific
expertise that we should be working with. We need to recognise that sometimes
the Australian supporting-research dollar isn't necessarily best
spent in Australia.
Although we have heard some
assurance that the different states are working a little better together
than they used to, we still don't have uniform regulations and often
I think the knowledge communication between those different bodies is
not good. We don't have national databases in many cases. Are we
on the way to putting those in place? Can we do better?
I think every group recognised
the need for more education of a wide range of stakeholders – of
the general public, of people involved in the particular industries, people
involved in trading, not only in production – and the need to recognise
that our awareness and surveillance have to go right along every part
of that business chain.
And then there is the question
of communication within science itself and between scientists and other
parts of industry and community, and of course to the politicians.
Finally, there is the inevitable
realisation now that even with some human diseases we can't just
think of humans as a source material. Other animals clearly are being
involved in the generation of some of our new viral diseases and perhaps
other diseases. A multidisciplinary response team or communication team
for these various threats is certainly much needed.
These are just some
of the universalities that have been identified in responding to emerging
diseases in the areas of human, animal, plant and aquatic health.
[Request is then made for a structured series of prioritised recommendations
from mixed breakout groups.]
top
of page |